In The Pipeline
• AEterna Zentaris has initiated a European multicenter Phase II trial of perifosine, a novel, first-in-class, oral signal transduction inhibitor, in combination with radiotherapy, in non-small cell lung cancer.
• CytRx Corp. has announced that the FDA has granted "fast-track" designation for the company’s leading drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis.
• CuraGen Corp. and TopoTarget A/S have announced the initiation of patient dosing in a Phase Ib open-label, multicenter, proof-of-concept clinical trial evaluating PXD101, a small molecule histone deacetylase inhibitor, for the treatment of advanced solid tumors, including colorectal cancer.
• CuraGen Corp. expects to complete the enrollment of patients in its Phase II randomized, double-blind, placebo-controlled clinical trial evaluating a single dose of velafermin (CG53135) for the prevention of oral mucositis in cancer patients undergoing bone marrow transplantation.
• ChemGenex Pharmaceuticals Limited has launched a new Phase II study evaluating the use of sHHT (Ceflatonin) in patients with accelerated-phase chronic myeloid leukemia who are resistant to the first-line therapy imatinib mesylate (Gleevec).
• Coley Pharmaceutical Group has initiated a five-arm Phase Ib clinical study of CPG 10101 (Actilon) alone and in combination with the current standard of care for the treatment of chronic hepatitis C virus.
• XTL Biopharmaceuticals Ltd. has initiated the Phase 1a clinical trial of XTL-6865 for the treatment of hepatitis C virus.
• ActivBiotics has announced plans to pursue a Phase II trial of its lead product, rifalazil, as a novel medical treatment for peripheral arterial disease.
• Koronis Pharmaceuticals has initiated a Phase 1b clinical trial of KP-1461, its novel anti-viral therapeutic, in HIV-positive patients.
• Alpharma has received clearance from the FDA to advance into a Phase II multidose clinical efficacy trial for an abuse-resistant, extended-release opioid. This product is being developed by the company for the treatment of chronic moderate-to-severe malignant (cancer-related) and non-malignant pain.
• Vion Pharmaceuticals has received fast track designation from the FDA for its anticancer agent VNP40101M (cloretazine) for induction treatment of patients older than 60 years of age with poor-risk acute myelogenous leukemia.
• Millennium Pharmaceuticals has initiated a Phase I/II, open-label, multicenter study of MLN518 in combination with standard induction chemotherapy in patients with newly diagnosed acute myelogenous leukemia.
• Schering-Plough Corp. has discontinued a Phase II study with its investigational CCR5 receptor antagonist, vicriviroc, used in combination with lamivudine/zidovudine (Combivir) in treatment-naive HIV patients. This decision was due to a return of detectable virus in some patients late in therapy compared to the control regimen of lamivudine/zidovudine and efavirenz (Sustiva), a current standard of care for treatment-naive patients living with HIV.
• Centocor and Eli Lilly & Co. have announced that patient enrollment in the Phase III trial of abciximab (Reopro) for the treatment of acute ischemic stroke has been permanently discontinued.
AEterna Zentaris has initiated a European multicenter Phase II trial of perifosine, a novel, first-in-class, oral signal transduction inhibitor, in combination with radiotherapy, in non-small cell lung cancer.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.